ScinoPharm Taiwan Balance Sheet Health
Financial Health criteria checks 6/6
ScinoPharm Taiwan has a total shareholder equity of NT$10.4B and total debt of NT$35.7M, which brings its debt-to-equity ratio to 0.3%. Its total assets and total liabilities are NT$11.8B and NT$1.3B respectively. ScinoPharm Taiwan's EBIT is NT$446.4M making its interest coverage ratio -8.8. It has cash and short-term investments of NT$4.0B.
Key information
0.3%
Debt to equity ratio
NT$35.70m
Debt
| Interest coverage ratio | -8.8x |
| Cash | NT$3.98b |
| Equity | NT$10.44b |
| Total liabilities | NT$1.34b |
| Total assets | NT$11.78b |
Recent financial health updates
Recent updates
ScinoPharm Taiwan's (TWSE:1789) Shareholders Will Receive A Smaller Dividend Than Last Year
Jun 17
Investors In ScinoPharm Taiwan, Ltd. (TPE:1789) Should Consider This, First
Apr 04A Look At The Intrinsic Value Of ScinoPharm Taiwan, Ltd. (TPE:1789)
Mar 14Weak Financial Prospects Seem To Be Dragging Down ScinoPharm Taiwan, Ltd. (TPE:1789) Stock
Feb 21ScinoPharm Taiwan's (TPE:1789) Shareholders Are Down 45% On Their Shares
Jan 25
We Think ScinoPharm Taiwan (TPE:1789) Can Manage Its Debt With Ease
Jan 04Estimating The Intrinsic Value Of ScinoPharm Taiwan, Ltd. (TPE:1789)
Dec 14Are Poor Financial Prospects Dragging Down ScinoPharm Taiwan, Ltd. (TPE:1789 Stock?
Nov 23Financial Position Analysis
Short Term Liabilities: 1789's short term assets (NT$6.5B) exceed its short term liabilities (NT$694.0M).
Long Term Liabilities: 1789's short term assets (NT$6.5B) exceed its long term liabilities (NT$650.4M).
Debt to Equity History and Analysis
Debt Level: 1789 has more cash than its total debt.
Reducing Debt: 1789's debt to equity ratio has reduced from 2.6% to 0.3% over the past 5 years.
Debt Coverage: 1789's debt is well covered by operating cash flow (1553.7%).
Interest Coverage: 1789 earns more interest than it pays, so coverage of interest payments is not a concern.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/30 19:59 |
| End of Day Share Price | 2024/12/30 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
ScinoPharm Taiwan, Ltd. is covered by 13 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ti-Rung Huang | Barclays |
| Pinghan Hsieh | Capital Securities Corporation |
| Christine Wang | Daiwa Securities Co. Ltd. |